Moderna Stock Slumps as Citi Says It’s Time to Sell After 500% Rally This Year

Nasdaq rose while S&P 500 dipped, both indexes gaining quarterly. August PCE inflation was 3.4% vs. 3.7% estimate, reducing Fed rate hike expectations. Q2 GDP revised to 2.2% growth. Microsoft, Apple, and Nvidia led tech gains. Moderna fell 5.3% after a downgrade. Private payrolls rose by 90,000 in September.

Moderna (MRNA) stock fell 8.23% on Wednesday after appointing a new COO and announcing the retirement of another executive. The company expanded its infectious disease franchise with new FDA and EC approvals for flu vaccines. Positive Phase 3 trial results for its individualized cancer therapy were also reported. The FDA approved updated COVID-19 vaccine formulas for 2026-2027.

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

Moderna (MRNA) shares fell 6.68% to $189.86 on Wednesday after announcing the addition of a Chief Operating Officer role. Juan Andres will fill the position, while Jerh Collins will retire. The stock has traded between $184.58 and $196.83 during the session, with volume at 8.54 million shares.

Moderna (MRNA) shares fell 6% after Citigroup downgraded the stock to Sell, citing unsustainable valuation and unrealistic revenue expectations. The analyst noted that Moderna's market cap rivals Regeneron despite lower expected revenue. Moderna's stock has been volatile, with a 520% gain year-to-date but a 5-year loss for early investors.

Moderna (MRNA) shares fell 7% to near $185 after Citi downgraded the stock to Sell, citing valuation concerns and legal risks. The decline follows a six-week rally to $210, driven by optimism around its cancer vaccine pipeline. Analysts question whether the stock's valuation is justified given near-term profitability uncertainties and ongoing patent litigation.